• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

ADHD Medication During Pregnancy and Breastfeeding

The decision to stop or continue ADHD medications during pregnancy and breastfeeding is a difficult decision for women suffering from the condition. Little data exists about how long-term exposure to these medications can affect the fetus.

A recent study published in Molecular Psychiatry demonstrates that children exposed to ADHD medication during pregnancy do not develop neurological issues like hearing loss or vision, febrile seizures or IQ impairment. The authors acknowledge the need for higher-quality research.

Risk/Benefit Analysis

Women who are pregnant and take ADHD medication need to consider the benefits of taking it against the potential risks for the baby. The doctors don't have the information to provide clear recommendations, but can provide information on risks and benefits to assist pregnant women to make an informed decision.

A study published in Molecular Psychiatry found that women who were taking ADHD medications during their early pregnancy did not have an increased risk of fetal cardiac malformations or major structural birth defects. Researchers used a vast population-based case-control study to evaluate the incidence of major structural birth defects in babies born to mothers who had taken stimulants in the early stages of pregnancy, as well as those who had not. Pediatric cardiologists and clinical geneticists reviewed the cases to ensure an accurate classification of the cases and to reduce the chance of bias.

However, the researchers' study was not without its flaws. The researchers were unable, in the first place, to separate the effects caused by the medication from the disorder. This makes it difficult for researchers to establish whether the few associations observed between the exposed groups were due to the use of medications or if they were confounded by co-morbidities. The researchers did not examine long-term outcomes for offspring.

The study did show that babies whose mothers had taken ADHD medication during pregnancy were at slightly higher risk of being admitted to the neonatal intensive care unit (NICU) than infants who prescribes adhd medication whose mothers did not take any medication or had taken off their medication prior to or during pregnancy. This was due to central nervous system disorders. The higher risk of admission was not influenced by the stimulant medication that was used during pregnancy.

Women who were taking stimulant ADHD medications during pregnancy also had a higher chance of having a caesarean section or one whose baby scored low on the Apgar scale (less than 7). These increases appeared to be independent types of adhd medication the type of medication used during pregnancy.

The research suggests that the low risk associated with the use of ADHD medications during the early stages of pregnancy could be offset by the greater benefits to both the mother and child of continuing treatment for the woman's disorder. Physicians should discuss this with their patients and, if possible, assist them in developing strategies to improve their coping abilities that may minimize the impact of her disorder on her daily life and relationships.

Medication Interactions

Many doctors are faced with the decision of whether to keep treatment or stop it during pregnancy as more women are diagnosed with ADHD. Often, these decisions are made in the absence of solid and reliable evidence in either case, which means that doctors have to weigh their experience about their experiences, the experiences of other doctors, and what research suggests about the subject, along with their best medication for adhd and anxiety judgment for each patient.

The issue of potential risks for infants can be difficult to determine. The research on this issue is based on observations rather than controlled studies, and many of the findings are conflicting. Additionally, the majority of studies limit their analysis to live births, which could undervalue the serious teratogenic effects that can cause abortion or termination of the pregnancy. The study that is discussed in this journal club addresses these limitations by examining data on both live and deceased births.

The conclusion: While some studies have found that there is a positive correlation between ADHD medications and the risk of certain birth defects, others have found no such relationship, and most studies show a neutral or even slightly negative effect. In the end an accurate risk-benefit analysis must be conducted in every case.

It can be challenging, if not impossible, for women suffering from ADHD to stop taking their medication. In fact, in an article recently published in Archives of Women's Mental Health, psychologist Jennifer Russell notes that stopping ADHD medication during pregnancy can lead to increased depression, feelings of isolation and family conflict for those suffering from the disorder. A decrease in medication could affect the ability to drive safely and complete work-related tasks, which are vital aspects of everyday life for those with ADHD.

She recommends women who are uncertain about whether to continue or stop medication in light of their pregnancy consider informing family members, friends and colleagues about the condition, its effects on daily functioning, and on the advantages of staying on the current treatment regimen. It can also help a woman feel confident about her decision. It is important to note that some medications are able to be absorbed through the placenta so if a woman decides to discontinue her buy adhd medication uk medication during pregnancy and breastfeeding, she must be aware that traces of the medication could be passed on to the baby.

Risk of Birth Defects

As the use and use of ADHD medication to treat symptoms of attention deficit hyperactivity disorder (ADHD) increases as does the concern about the potential adverse effects of the drugs on foetuses. A study that was published in the journal Molecular Psychiatry adds to the existing information on this topic. Researchers used two massive data sets to study more than 4.3 million pregnancy and determine if the use of stimulant medications increased birth defects. Researchers discovered that although the risk overall is low, first-trimester ADHD exposure to medication was associated with slightly higher rates of specific heart defects like ventriculoseptal defect.

The researchers behind the study found no association between early use of medication and other congenital anomalies, such as facial clefting or club foot. The results are in line with previous studies showing a small but significant increase in the risk of developing cardiac malformations among women who began taking ADHD medications prior to the time of the time of pregnancy. This risk increased in the latter half of pregnancy, as many women begin to discontinue their ADHD medications.

Women who were taking ADHD medication in the first trimester were more likely to require a caesarean birth or have a low Apgar after birth and have a baby that needed help breathing when they were born. The authors of the study were not able to eliminate selection bias because they limited their study to women without other medical conditions that might have contributed to the findings.

The researchers hope that their research will serve to inform the clinical decisions of doctors who encounter pregnant women. The researchers suggest that, while discussing benefits and risks are important, the decision on whether to continue or stop medication should be based on the severity of each woman's ADHD symptoms and the needs of the woman.

The authors warn that, while stopping the medication is a possibility to think about, it isn't recommended due to the high prevalence of depression and other mental problems for women who are pregnant or have recently given birth. Additionally, the research suggests that women who decide to stop taking their medication are more likely to have difficulties getting used to life without them following the baby's arrival.

Nursing

The responsibilities that come with being a new mom can be overwhelming. Women suffering from ADHD can face severe challenges when they must manage their symptoms, attend doctor appointments, prepare for the birth of their child and adjust to a new routine. Many women opt to continue taking their ADHD medication during pregnancy.

The majority of stimulant medications are absorbed by breast milk in small quantities, so the risk to the infant who is breastfeeding is low. The rate of exposure to medication will vary based on the dosage, frequency of administration and time of day. Additionally, individual medications enter the baby's system differently through the gastrointestinal tract as well as breast milk. The impact of this on a newborn infant is not well understood.

Due to the absence of research, some physicians may be inclined to discontinue stimulant drugs during the pregnancy of a woman. This is a difficult decision for the woman who must weigh the advantages of her medication against the potential risks to the foetus. In the meantime, until more information is available, GPs can inquire about pregnant patients whether they have an background of ADHD or if they are planning to take medication in the perinatal phase.

A growing number of studies have proven that the majority of women are able to safely continue their ADHD medication during pregnancy and breastfeeding. As a result, an increasing number of patients opt to do this and in consultation with their doctor they have discovered that the benefits of maintaining their current medication far exceed any risk.

Women who suffer from ADHD who are planning to breastfeed should seek the advice of an expert psychiatrist prior to becoming pregnant. They should discuss their medication with their doctor and discuss the pros and cons of continuing treatment. This includes non medication treatment for adhd-pharmacological methods. Psychoeducation is also needed to help pregnant women suffering from ADHD be aware of the symptoms and underlying disorder. They should also learn about treatment options and strengthen coping mechanisms. This should be a multidisciplinary process including obstetricians, GPs and psychiatrists. The pregnancy counselling should consist of the discussion of a plan for management for both the mother and child, as well as monitoring for signs of deterioration, and, if necessary, adjustments to the medication regimen.